Strategic funding Microba has secured recent funding rounds totaling over $25M and a fresh $14.5M injection to accelerate clinical rollout, partnerships, and profitability. This presents an opportunity to propose expanded microbiome testing programs and payer/partner collaborations aligned with their growth capital needs.

Clinical expansion Recent launches and product milestones, including MetaPanel and MAP 315 progress, indicate an active push into clinical applications and drug development. Sales approaches can target healthcare systems, clinics, and pharma partners seeking scalable microbiome testing and therapeutic development support.

Partnerships focus Active partnerships and acquisitions, such as the Invivo Clinical acquirement and distribution agreements like MetaPanel with Sonic Healthcare, show a preference for collaboration. Target potential health networks, CPAs, and contract research organizations to extend the testing ecosystem.

Global collaboration MAP 315 GMP-scale collaboration with Bacthera for clinical supply indicates readiness for international clinical trials. Propose global supply agreements, regulatory-ready testing kits, and cross-border CRO partnerships to scale quickly.

Technology backbone A diverse tech stack (AWS, Google Cloud, Stripe, Dynamics, WordPress) supports scalable services and secure data handling. Leverage this to position integrated, enterprise-grade microbiome testing platforms for healthcare providers, payers, and partner networks with seamless billing and CRM workflows.